Astellas shares its community newsletter for the Duchenne community including an update on its Phase 1b Study: a study to assess the safety, tolerability and preliminary efficacy of ASP0367 (MA0211) in pediatric male participants with Duchenne muscular dystrophy (DMD). Click here to read the full newsletter.
Join Jett Foundation for a virtual presentation and live Q&A with Astellas on Wednesday, November 18, 2020 at 2:00PM ET. Register now!
